Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today it has completed its previously announced acquisition of Kolltan Pharmaceuticals, Inc.
In a research report published Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $7.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, Inc.
In a research report published Monday, Brean Capital analyst Jason Wittes reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a …
Brean Capital analyst Jason Wittes was out with a research report, assuming coverage on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), with a Buy rating and price target of …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the second quarter ended June 30, 2016.